English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  The objective of this study was to evaluate the effects of gene polymorphisms, including  UGT1A1*7 ,  *27 , and  *29 , on the safety of irinotecan therapy.    Methods  The eligibility criteria were: lung cancer patients scheduled to undergo irinotecan therapy, aged ≥ 20 years, with a performance status of 0–2. Thirty‐one patients were enrolled and their blood was collected and used to examine the frequency of  UGT1A1*6 ,  *7 ,  *27 , * 28 , and  *29  polymorphisms and the concentrations of irinotecan, SN‐38, and SN‐38G after irinotecan therapy.    Results  The patients’ characteristics were as follows: male/female 25/6, median age 71 years (range 55–84), stage IIB/IIIA/IIIB/IV 2/6/11/12, and adenocarcinoma/squamous cell carcinoma/small cell carcinoma/other 14/10/3/4, respectively. The −/−, *6/−, *7/−, *27/−, *28/−, and *29/−  UGT1A1  gene polymorphisms were observed in 10 (32%), 10 (32%), 2 (6%), 2 (6%), 7 (23%), and 0 (0%) cases, respectively. The  UGT1A1*27  polymorphism occurred separately from the  UGT1A1*28  polymorphism. The lowest leukocyte counts of the patients with the  UGT1A1*27  and  UGT1A1*6  gene polymorphisms were lower than those observed in the wild‐type patients. SN‐38 tended to remain in the blood for a prolonged period after the infusion of irinotecan in patients with  UGT1A1*27  or  UGT1A1*28  polymorphisms. No severe myelotoxicity was seen in the patients with  UGT1A1*7 .    Conclusion   UGT1A1*27  can occur separately from  UGT1A1*28  and is related to leukopenia during irinotecan treatment.  UGT1A1*7  is less relevant to irinotecan‐induced toxicities, and  UGT1A1*29  seems to have little clinical impact.

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer

Relationship between UGT1A127 and UGT1A17 polymorphisms and irinotecan‐related toxicities in patients with lung cancer